This brand name is authorized in Ireland, United Kingdom
The drug MENITORIX contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Haemophilus type b polysaccharide conjugated to tetanus toxoid as carrier protein
UNII C9R35M8XV6 - HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN
|
|
|
|
2
Neisseria meningitidis group C (strain C11) polysaccharide conjugated to tetanus toxoid as carrier protein
UNII ZT89E5A103 - NEISSERIA MENINGITIDIS GROUP C CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN
|
|
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J07AG53 | Haemophilus influenzae B, combinations with meningococcus C, conjugated | J Antiinfectives for systemic use → J07 Vaccines → J07A Bacterial vaccines → J07AG Haemophilus influenzae B vaccines |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 99038 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
